Angus Liu is a Deputy Editor at Fierce Pharma and Fierce Biotech. He focuses on the intersection of medicine and healthcare, particularly in pharmaceuticals, healthcare technology, and corporate finance, with a keen interest in topics such as pharmaceutical manufacturing, oncology, and digital health. Angus has been featured in Biotech, Fierce Pharma, and NewsBreak.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.
By: Angus Liu
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-
By: Angus Liu
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard
By: Angus Liu
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry.
By: Angus Liu
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
By: Angus Liu
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 results from China that
By: Angus Liu
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts.
By: Angus Liu
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvy
By: Angus Liu, Ayla Ellison, Darren Incorvaia, Zoey Becker
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann
By: Angus Liu
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.
